参麦川芎嗪注射液辅助治疗慢性肺源性心脏病的疗效观察.docVIP

参麦川芎嗪注射液辅助治疗慢性肺源性心脏病的疗效观察 　　【摘要】 目的 探讨参麦、川芎嗪注射液辅助治疗慢性肺源性心脏病（肺心病）的疗效。 　　方法 选择肺心病患者40例（治疗组），在常规治疗的基础上加用参麦注射液及川芎嗪注射液治疗14天，并与40例常规治疗组（对照组）比较，观察治疗前后两组患者二氧化碳分压（PaCO2）、血氧分压（PaO2）和脑钠肽（BNP）的变化情况。 　　结果 治疗组治疗前PaCO2、PaO2、BNP水平分别为（73.99±5.63）mmHg、（51.12±4.60）mmHg和（3264.73±671.66）pg/ml，治疗后为（5841±6.02）mmHg、（63.71±3.53）mmHg和（241.25±80.58）pg/ml；对照组治疗前为（73.90±4.75）mmHg、（51.09±398）mmHg和（3205.72±713.18）pg/ml，治疗后为（63.29±4.72）mmHg、（57.95±3.68）mmHg和（470.56±156.65）pg/ml。两组PaCO2、BNP治疗前水平较高，治疗后水平下降（P0.05），治疗后治疗组PaCO2、BNP水平较对照组低，PaO2水平较对照组高（P0.01），提示参麦注射液和川芎嗪注射液辅助治疗肺心病疗效优于常规治疗组。 　　结论 参麦注射液联合川芎嗪注射液辅助治疗肺心病可有效改善慢性肺源性心脏病患者血清PaCO2，PaO2和BNP水平，对改善患者心肺功能，提高临床疗效有益。 　　【关键词】 慢性肺源性心脏病肺；参麦注射液；川芎嗪注射液 　　中图分类号：R541.5 文献标识码：A DOI：10.3969/j.issn2015.05.003 　　Observation of the effects of Shenmai injection and ligustrazine injection in the adjuvant treatment of chronic pulmonary heart disease 　　[HJ1*2][HJ] 　　ZHANG Qiang1，LIANG Xianfeng1，HUANG Yansu1，LI Jindu2，LI Tianzi3 　　（1.Department of Cardiovasology and Respiratory Medicine，People’s Hospital of Jingxi，Jingxi 533800；2.The Second Class of Grade 2012 in Longtermsystem，Guangxi Medical University，Nanning 530021；3.Affiliated Hospital of Youjiang Medical University for Nationalities，Baise 533000，Guangxi，China） 　　[HJ1*2][HJ] 　　【Abstract】 Objective To investigate the effects of Shenmai injection and ligustrazine injection in the adjuvant treatment of chronic pulmonary heart disease. 　　Methods 40 cases of pulmonary heart disease （treatment group） were treated with Shenmai injection and ligustrazine injection for 14 days on the basis of conventional treatment，and they were compared to 40 cases （control group） who were treated with conventional treatment only.The changes of partial pressure of carbon dioxide（PaCO2），partial pressure of oxygen（PaO2） and brain natriuretic peptide （BNP） before and after treatment were observed in the two groups. 　　Results Before treatment，levels of PaCO2，PaO2 and BNP in the treatment group were（73.99±5.63）mmHg，（51.1